company background image
2269 logo

WuXi Biologics (Cayman) SEHK:2269 Stock Report

Last Price

HK$17.96

Market Cap

HK$73.6b

7D

4.4%

1Y

-36.6%

Updated

18 Jan, 2025

Data

Company Financials +

WuXi Biologics (Cayman) Inc.

SEHK:2269 Stock Report

Market Cap: HK$73.6b

2269 Stock Overview

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details

2269 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance2/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

WuXi Biologics (Cayman) Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for WuXi Biologics (Cayman)
Historical stock prices
Current Share PriceHK$17.96
52 Week HighHK$32.25
52 Week LowHK$10.14
Beta0.57
1 Month Change5.90%
3 Month Change8.85%
1 Year Change-36.65%
3 Year Change-79.96%
5 Year Change-48.44%
Change since IPO90.73%

Recent News & Updates

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Dec 17
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Recent updates

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Dec 17
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Shareholder Returns

2269HK Life SciencesHK Market
7D4.4%0.2%2.1%
1Y-36.6%-31.6%23.7%

Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -31.6% over the past year.

Return vs Market: 2269 underperformed the Hong Kong Market which returned 23.7% over the past year.

Price Volatility

Is 2269's price volatile compared to industry and market?
2269 volatility
2269 Average Weekly Movement6.5%
Life Sciences Industry Average Movement7.4%
Market Average Movement6.6%
10% most volatile stocks in HK Market14.0%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2269 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2269's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201412,435Chris Chenwww.wuxibiologics.com

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.

WuXi Biologics (Cayman) Inc. Fundamentals Summary

How do WuXi Biologics (Cayman)'s earnings and revenue compare to its market cap?
2269 fundamental statistics
Market capHK$73.58b
Earnings (TTM)HK$2.80b
Revenue (TTM)HK$18.19b

26.3x

P/E Ratio

4.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2269 income statement (TTM)
RevenueCN¥17.12b
Cost of RevenueCN¥10.50b
Gross ProfitCN¥6.62b
Other ExpensesCN¥3.99b
EarningsCN¥2.63b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.64
Gross Margin38.66%
Net Profit Margin15.38%
Debt/Equity Ratio4.8%

How did 2269 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 23:14
End of Day Share Price 2025/01/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 56 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Bo LiBofA Global Research